摘要
目的探讨瑞舒伐他汀与阿托伐他汀治疗冠心病的临床效果。方法选择在我院治疗的冠心病患者82例,采取随机分组的方法将患者分为对照组和观察组,每组41例。对照组采用阿托伐他汀治疗,观察组采用瑞舒伐他汀治疗。对两组患者的治疗效果进行比较。结果治疗前两组患者各项血脂水平比较,差异无统计学意义(P>0.05);治疗后,两组患者各项血脂水平均明显改善(P<0.05),且观察组TC、TG、LDL-C均显著低于对照组,HDL-G显著高于对照组(P<0.05)。对照组的不良反应发生率(24.39%)明显高于观察组(7.32%)(P<0.05)。结论与阿托伐他汀相比采用瑞舒伐他汀治疗冠心病效果更为显著,安全性更高,可在临床中推广应用。
Objective To invesligale the clinical effecl of rosuvaslalin and alorvaslalin in the Irealmenl of coronary heart disease. Methods Eighly-lwo cases of palienls with coronary heart disease treated in our hospital were selected and randomly divided inlo conlrol group and observalion group, wilh 41 cases in each group. The conlrol group was lrealed with alorvaslalin, while lhe observalion group was lrealed wilh rosuvaslalin. The clinical effecl of lhe lwo groups were compared. Results There was no significant difference of blood lipid levels between lhe lwo groups before treatment （ P 〉0.05）, after treatment, lhe blood lipid levels of lhe lwo groups were obviously improved （P〈0.05）, lhe TC, TG, LDL-C in lhe observalion group were significantly lower than those in lhe conlrol group, and lhe HDL-G in lhe observalion group was significantly higher than lhal in conlrol group （P 〈0.05）. The adverse reactions rale of lhe conlrol group （24.39%） was significantly higher than lhal in observalion group （7.32%）（P 〈0.05）. Conclusion Compared wilh alorvaslalin, lhe effecl of rosuvaslalin in lhe treatment of coronary heart disease is significantly and has higher safely, which can be widely used in clinical.
作者
郭华平
GUO Hua-ping(Deparlmenl of Medicine Baishui Counly Hospital, Weinan 715600, China)
出处
《临床医学研究与实践》
2017年第5期20-21,共2页
Clinical Research and Practice
关键词
瑞舒伐他汀
阿托伐他汀
冠心病
rosuvaslalin
alorvaslalin
coronary heart disease
